Company intelligence / Profile preview

TRON

Mainz, Rhineland-Palatinate, Germany

Ownership: Public · TRON
Development stage: Other

Overview

TRON focuses on translating advanced basic research in genomics and immunology into innovative diagnostics and therapeutic platforms primarily for oncology; clinical outcomes are predominantly pre-clinical and platform/biomarker validation.

Therapeutic areas: OncologyOther
Modalities: Monoclonal antibodyGene therapyAdoptive cell therapyVaccineSmall moleculeBiologic
Industry: Academic Hospital/University/Research

Partnerships

Academic institutionsBiotech companiesPharmaceutical industry

Financials

Market cap: $759M
Total revenue: $1.6M
Enterprise value: $750.1M

Beyond the preview

Go deeper on TRON.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRON.

Explore the full profile